Amylin continues to show benefits

///Amylin continues to show benefits
Facebooktwittergoogle_plusredditlinkedinmail
Diabetes Bites Newsletter

Amylin continues to show benefits

Amylin infusion improves time in range and variability over insulin only artificial pancreas system.

When we discuss the future of insulin delivery technology the topic of dual hormone therapy typically comes up. Typically we are thinking of those hormones as insulin and glucagon, with insulin lowering blood sugars while glucagon prevents hypoglycemia.

However, in a recent study presented at The American  Diabetes Association’s 78th Scientific Sessions, results of a dual hormone artificial pancreas system were presented. In this case the hormones used were Insulin and Amylin. 

What is Amylin?

Amylin is a hormone secreted with insulin by pancreatic beta cells. This hormone reduces glucagon secretion, slows gastric emptying and increases satiety. But, due to the beta cell damage that leads to type 1 diabetes, people with type 1 diabetes also lose our ability to produce amylin. 

In a three session controlled test patients found a 12% increase in time in target range during daytime hours using a fixed ratio of amylin to rapid acting insulin in comparison to rapid insulin only. (Both of which out performed regular insulin/amylin delivery).

Overnight use shows that rapid acting insulin only systems showed 6%higher more time in range with rapid acting/amylin just behind. (again regular/amylin delivery falling well short) it was also found that participants using the rapid/amylin delivery showed reduced glycemic variability over the study period. 

One of the largest limiting factors in current amylin supplementation therapies is nausea sometimes associated with medications. In this study 1/6 participants reported nausea. 

This study demonstrates that the co infusion of rapid acting insulin with amylin demonstrates improved time in range and reduced variation. perhaps rather than dual hormone therapy, we should be anticipating tri-hormone therapy from our future artificial pancreas systems. 

you can find further study details here: https://plan.core-apps.com/tristar_ada18/abstract/807d2f9885450670bb994661e3654056

Back to September 2018 Newsletter
By |2018-09-02T17:51:31+00:00September 2nd, 2018|Diabetes Bites, September 2018 Newsletter|1 Comment

About the Author:

Integrated Diabetes Services is the worldwide leader in one-on-one consulting for people who use insulin. Diabetes “coaching” services are available in-person and remotely via phone and the internet for children and adults.

One Comment

  1. Bethany September 7, 2018 at 2:36 am - Reply

    Symlin and pregnancy/breastfeeding… is there any reason that is not recommended but injected insulin and breastfeeding are totally fine? Aren’t they both just synthetic hormones?

Leave A Comment